Age-Related Macular Degeneration: From Epigenetics to Therapeutic Implications

Adv Exp Med Biol. 2021:1256:221-235. doi: 10.1007/978-3-030-66014-7_9.

Abstract

Aberrant regulation of epigenetic mechanisms, including the two most common types; DNA methylation and histone modification have been implicated in common chronic progressive conditions, including Alzheimer disease, cardiovascular disease, and age-related macular degeneration (AMD). All these conditions are complex, meaning that environmental factors, genetic factors, and their interactions play a role in disease pathophysiology. Although genome wide association studies (GWAS), and studies on twins demonstrate the genetic/hereditary component to these complex diseases, including AMD, this contribution is much less than 100%. Moreover, the contribution of the hereditary component decreases in the advanced, later onset forms of these chronic diseases including AMD. This underscores the need to elucidate how the genetic and environmental factors function to exert their influence on disease pathophysiology. By teasing out epigenetic mechanisms and how they exert their influence on AMD, therapeutic targets can be tailored to prevent and/or slow down disease progression. Epigenetic studies that incorporate well-characterized patient tissue samples (including affected tissues and peripheral blood), similar to those relevant to gene expression studies, along with genetic and epidemiological information, can be the first step in developing appropriate functional assays to validate findings and identify potential therapies.

Keywords: Age-related macular degeneration; Chromatin; Epigenetics; Functional assays; Genetics; Histone modification; Induced pluripotent stem cells; Methylation; Therapies.

MeSH terms

  • DNA Methylation
  • Epigenesis, Genetic
  • Epigenomics
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study*
  • Humans
  • Macular Degeneration* / genetics
  • Macular Degeneration* / therapy